Treatment of Iron Deficiency with Normal Iron Binding Capacity

First-Line Treatment: Oral Iron Supplementation

The British Society of Gastroenterology recommends starting with one tablet per day of ferrous sulphate (200 mg), ferrous fumarate, or ferrous gluconate as initial therapy 1
Start with 50-100 mg elemental iron once daily (e.g., ferrous sulphate 200 mg = 65 mg elemental iron) 1, 2

Continue iron supplementation for 3 months after correction of anemia to adequately replenish iron stores 3, 4, 1, 5, 6, 7
Monitor hemoglobin response at 4 weeks—expect a rise of approximately 2 g/dL after 3-4 weeks of treatment 5, 8

Parenteral iron should be considered when oral iron is contraindicated, ineffective, or not tolerated 1, 2
Indications for parenteral iron include intolerance to at least two oral iron preparations 5, 8, non-compliance with oral therapy 5, 8, malabsorption (e.g., celiac disease, inflammatory bowel disease with active inflammation) 9, 10, and continued blood loss despite oral supplementation 10

Iron sucrose (Venofer): 200 mg over 10 minutes 3, 4, 6, 7
Ferric carboxymaltose (Ferinject): 1000 mg over 15 minutes 3, 4, 6, 7
Iron dextran (Cosmofer): 20 mg/kg over 6 hours (higher risk of anaphylaxis—0.6-0.7%) 3, 4, 6, 7

Ascorbic acid (250-500 mg twice daily) may enhance iron absorption when taken with oral iron, though evidence for clinical effectiveness is limited 3, 4, 6, 7
Treat underlying causes of iron deficiency (e.g., gastrointestinal bleeding, menorrhagia, malabsorption) to prevent recurrence 3, 4, 6

Monitor hemoglobin and red cell indices every 3 months for the first year, then annually 3, 5, 8, 6
After restoration of iron stores, monitor blood counts every 6 months initially to detect recurrent deficiency 1, 2
Reinitiate iron supplementation if hemoglobin or MCV falls below normal 5, 8

Do not delay iron replacement therapy while awaiting diagnostic workup unless colonoscopy is imminent 1, 2
Do not assume normal IBC excludes iron deficiency—ferritin and transferrin saturation are more reliable markers 9, 10
Do not use modified-release preparations—they are less suitable for prescribing due to unpredictable absorption 1, 2
Failure to respond to oral iron is usually due to poor compliance, misdiagnosis, continued blood loss, or malabsorption—not inadequate dosing 5, 8

The American Gastroenterological Association recommends that patients with iron deficiency anemia who have failed oral iron supplementation should be treated with intravenous iron therapy, as oral iron may not be absorbed or may not be taken properly, leading to persistent severe iron depletion 11, 12, 13
The European Society for Clinical Nutrition and Metabolism suggests that ferric carboxymaltose (Ferinject) is a preferred first-line IV option, which can be administered as a single dose of 1000 mg over 15 minutes, due to its convenience and excellent safety profile 11, 12, 13
The American College of Gastroenterology recommends calculating the total iron deficit, which can be approximately 1000-1500 mg of total elemental iron for a patient with depleted iron stores, and using a single infusion of ferric carboxymaltose 1000 mg to replace iron deficits efficiently 11, 12, 13

The National Institute for Health and Care Excellence recommends rechecking labs in 8-10 weeks after IV iron infusion, as ferritin levels will be falsely elevated immediately post-infusion, and monitoring hemoglobin, ferritin, transferrin saturation, MCV, MCH, and MCHC to assess response to treatment 12
The American Society of Hematology suggests long-term monitoring of CBC and iron indices every 3 months for the first year, then annually, to ensure that iron deficiency anemia does not recur 13

The European Society of Gastrointestinal Endoscopy recommends investigating the underlying cause of iron deficiency anemia, including gastrointestinal blood loss, malabsorption disorders, menstrual losses, and medication interference, to determine the best course of treatment 11, 13
The American College of Gastroenterology suggests testing for celiac disease with tissue transglutaminase antibodies (tTG) in patients with iron deficiency anemia, as celiac disease can affect up to 4% of women with iron deficiency anemia 11, 13